Company · Private

Deciduous Therapeutics

Develops small molecules that recruit the innate immune system to clear senescent cells rather than killing them directly.

Listing

Private

Ticker

—

Headquarters

San Francisco, US

Founded

2019

Technology

Immune-mediated senescent cell clearance

Longevity thesis

Immune clearance may produce durable benefit with lower off-target toxicity than direct-kill senolytics.

Programmes

DT-201Preclinical
Metabolic disease

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.